BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 29881958)

  • 1. Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism.
    Coleman CI; Turpie AGG; Bunz TJ; Beyer-Westendorf J
    J Thromb Thrombolysis; 2018 Oct; 46(3):339-345. PubMed ID: 29881958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism.
    Coleman CI; Turpie AGG; Bunz TJ; Beyer-Westendorf J
    Am J Med; 2018 Aug; 131(8):933-938.e1. PubMed ID: 29526541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state.
    Coleman CI; Turpie AGG; Bunz TJ; Baker WL; Beyer-Westendorf J
    Thromb Res; 2018 Mar; 163():132-137. PubMed ID: 29407625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism.
    Kohn CG; Bunz TJ; Beyer-Westendorf J; Coleman CI
    Eur J Haematol; 2019 Feb; 102(2):143-149. PubMed ID: 30328143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data.
    Costa OS; Beyer-Westendorf J; Ashton V; Milentijevic D; Moore KT; Bunz TJ; Coleman CI
    J Thromb Thrombolysis; 2021 Feb; 51(2):349-358. PubMed ID: 32588288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of rivaroxaban versus warfarin in patients with unprovoked venous thromboembolism: A propensity-score weighted administrative claims cohort study.
    Coleman CI; Peacock WF; Bunz TJ; Beyer-Westendorf J
    Thromb Res; 2018 Aug; 168():31-36. PubMed ID: 29883907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTE.
    Coleman CI; Turpie AGG; Bunz TJ; Beyer-Westendorf J; Baker WL
    Am J Med; 2019 Apr; 132(4):498-504. PubMed ID: 30582894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism.
    Coleman CI; Beyer-Westendorf J; Bunz TJ; Mahan CE; Spyropoulos AC
    Clin Appl Thromb Hemost; 2018 May; 24(4):575-582. PubMed ID: 29514466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
    Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
    Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
    Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
    JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs.
    Spyropoulos AC; Ashton V; Chen YW; Wu B; Peterson ED
    Thromb Res; 2019 Oct; 182():159-166. PubMed ID: 31493618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer.
    Streiff MB; Milentijevic D; McCrae K; Yannicelli D; Fortier J; Nelson WW; Laliberté F; Crivera C; Lefebvre P; Schein J; Khorana AA
    Am J Hematol; 2018 May; 93(5):664-671. PubMed ID: 29396864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients.
    Fung KP; Chan KH; Ng V; Tsui PT; You JHS
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):331-337. PubMed ID: 30888571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
    Raskob G; Ageno W; Cohen AT; Brekelmans MP; Grosso MA; Segers A; Meyer G; Verhamme P; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
    Lancet Haematol; 2016 May; 3(5):e228-36. PubMed ID: 27132697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism in African American patients: a retrospective cohort analysis.
    Costa OS; Thompson S; Ashton V; Palladino M; Bunz TJ; Coleman CI
    Thromb J; 2020; 18():6. PubMed ID: 32292291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States.
    Berger JS; Laliberté F; Kharat A; Lejeune D; Moore KT; Jung Y; Lefebvre P; Ashton V
    J Thromb Thrombolysis; 2022 Oct; 54(3):438-448. PubMed ID: 35562510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ; San Agustin K; DeAngelo J; Campbell AM
    Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
    Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
    Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.